Second Interim Analysis Of The 'Use Via Early Access To Ixazomib' Study: A European, Multicentre, Observational, Longitudinal Cohort Study Of The Effectiveness And Safety Of Ixazomib-Based Therapy In Patients With Relapsed/Refractory Multiple Myeloma Treated Outside Of The Clinical Trial Setting Via An Early Access Programme: Uk Subgroup Analysis